OrbiMed Capital GP VI LLC's Net Worth

$1.07 Billion

Who is OrbiMed Capital GP VI LLC?

OrbiMed Capital GP VI LLC has an estimated net worth of $1.07 Billion. This is based on reported shares across multiple companies, which include Adicet Bio, Inc., LogicBio Therapeutics, Inc., 89bio, Inc., SteadyMed Ltd., AVEDRO INC, Turning Point Therapeutics, Inc., CONSTELLATION PHARMACEUTICALS INC, Prelude Therapeutics Inc, Crinetics Pharmaceuticals, Inc., Verona Pharma plc, ALPINE IMMUNE SCIENCES, INC., CTI BIOPHARMA CORP, NeuroPace Inc, Edgewise Therapeutics, Inc., Ikena Oncology, Inc., ARVINAS INC., Prevail Therapeutics Inc., ARS Pharmaceuticals, Inc., Disc Medicine, Inc., GRAYBUG VISION, INC., Oric Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., scPharmaceuticals Inc., NextCure, Inc., SYNLOGIC, INC., SpringWorks Therapeutics, Inc., and Turnstone Biologics Corp..

SEC CIK

OrbiMed Capital GP VI LLC's CIK is 0001682115

Past Insider Trading and Trends

2020 was OrbiMed Capital GP VI LLC's most active year for acquiring shares with 31 total transactions. OrbiMed Capital GP VI LLC's most active month to acquire stocks was the month of December. 2021 was OrbiMed Capital GP VI LLC's most active year for disposing of shares, totalling 49 transactions. OrbiMed Capital GP VI LLC's most active month to dispose stocks was the month of February. 2020 saw OrbiMed Capital GP VI LLC paying a total of $111,888,105.01 for 64,654,696 shares, this is the most they've acquired in one year. In 2021 OrbiMed Capital GP VI LLC cashed out on 48,733,244 shares for a total of $137,125,898.41, their largest year based on trade value.